Syngene revenue from operations up 17 per cent in Q2FY22
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company claims that its Empagliflozin tablets are the most affordable in India
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
The BiCNU brand and generic market had U.S. sales of approximately US $ 19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
Subscribe To Our Newsletter & Stay Updated